| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tumor necrosis factor receptor superfamily member 11B;Osteoclastogenesis inhibitory factor;Osteoprotegerin;Tnfrsf11b;Ocif, Opg; |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Expression System | |
| Gene ID | |
| Immunogen | Expression system for standard: NS0; Immunogen sequence: E22-L401 |
| Product Type | |
| Reactivity | |
| Sample Type(s) | cell culture supernatants, serum and plasma (EDTA). |
| Sensitivity | |
| Storage | |
| Target | |
| UniProt # |
Background
Also known as: Tumor necrosis factor receptor superfamily member 11B, Osteoclastogenesis inhibitory factor, Osteoprotegerin, Tnfrsf11b, Ocif, Opg.
Mouse OPG (TNFRSF11B) / Osteoprotegerin (TNFRSF11B) is an established target in many assay panels, supporting hypothesis testing across diverse biological systems. This target is frequently investigated in Molecular & Cellular Biology research contexts. Cytokines and chemokines act as soluble messengers that coordinate immune cell activation, trafficking, and effector functions. Their concentrations can change rapidly in response to infection, tissue injury, or immune stimulation.
Biological function and signaling context
In immune signaling networks, cytokine production is often induced by pattern-recognition pathways and inflammatory transcriptional programs, while feedback regulators can dampen responses to restore homeostasis. Chemokine gradients guide leukocyte migration, influencing which cell populations accumulate at a site and how long they persist.
Why it matters in research
- Immune activation readout: Shifts in abundance can reflect pathway engagement and cellular activation state.
- Microenvironment profiling: Levels can help characterize inflammatory tone in tissues or biofluids.
- Response monitoring: Time-course measurements support interpretation of stimulus, treatment, or infection models.
Disease and translational relevance
Many cytokines and chemokines are reported to associate with inflammatory, autoimmune, infectious, and oncology-related processes. In research settings, interpreting changes benefits from pairing this analyte with complementary markers (e.g., upstream triggers, downstream effectors, and cell-type indicators) and considering matrix effects.
Sample data
| Concentration (pg/ml) | 0 | 93.8 | 187.5 | 375 | 750 | 1500 | 3000 | 6000 |
| O.D. | 0.014 | 0.071 | 0.138 | 0.275 | 0.536 | 0.92 | 1.532 | 2.158 |
Intra/inter assay consistency
| Intra-Assay Precision | Inter-Assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 16 | 16 | 16 | 24 | 24 | 24 |
| Mean (pg/ml) | 133 | 800 | 3535 | 139 | 767 | 3643 |
| Standard deviation | 5.85 | 54.4 | 187.35 | 7.39 | 55.39 | 225.86 |
| CV (%) | 4.4% | 6.8% | 5.3% | 4.6% | 7.3% | 6.2% |
Kit components
Description|Quantity Pre-coated 96-well strip microplate|1 Standard|2 vials Biotinylated antibody (100x)|100ul Avidin-Biotin-Peroxidase Complex (100x)|100ul Sample Diluent|30ml Antibody Diluent|12ml Avidin-Biotin-Peroxidase Diluent|12ml Color Developing Reagent (TMB)|10ml Stop Solution|10ml Wash Buffer (25x)|20ml Adhesive plate sealers|4Materials required but not provided
- Microplate Reader capable of reading absorbance at 450nm.
- Incubator.
- Automated plate washer (optional).
- Pipettes and pipette tips capable of precisely dispensing 0.5 µl through 1 ml volumes of aqueous solutions.
- Multichannel pipettes are recommended for large amount of samples.
- Deionized or distilled water.
- 500ml graduated cylinders.
- Test tubes for dilution.
►How many samples can I run per plate?
►What sample dilution should I use?
►Why is my signal weak or absent?
►Why is my background signal high?
►Are the kit components sterile?
►How do I analyze my ELISA results?
►How should I store samples before running the assay?
►What positive and negative controls should I include?
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
- Liu et al. (2024). Stephanine Protects Against Osteoporosis by Suppressing Osteoclastogenesis via Inhibition of the RANKL—RANK Interaction. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE.
- Marianne et al. (2024). Differential effects of alendronate on chondrocytes, cartilage matrix and subchondral bone structure in surgically induc…. Scientific Reports.
- Zhang et al. (2023). Plasma TNFRSF11B as a New Predictive Inflammatory Marker of Sepsis–ARDS with Endothelial Dysfunction. JOURNAL OF PROTEOME RESEARCH.
- Huang et al. (2022). Oroxin B Attenuates Ovariectomy-Induced Bone Loss by Suppressing Osteoclast Formation and Activity. Drug Design Development and Therapy.
- Yang et al. (2022). NTCP Deficiency Affects the Levels of Circulating Bile Acids and Induces Osteoporosis. Frontiers in Endocrinology.
- Deepak et al. (2022). IFT80 negatively regulates osteoclast differentiation via association with Cbl-b to disrupt TRAF6 stabilization and acti…. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.
- Li et al. (2022). IFT20 governs mesenchymal stem cell fate through positively regulating TGF-β-Smad2/3-Glut1 signaling mediated glucose me…. Redox Biology.
- Li et al. (2022). Deletion of Trp53 and Rb1 in Ctsk-expressing cells drives osteosarcoma progression by activating glucose metabolism and …. MedComm.
- Li et al. (2021). Introduction of a Cys360Tyr Mutation in ANO5 Creates a Mouse Model for Gnathodiaphyseal Dysplasia. JOURNAL OF BONE AND MINERAL RESEARCH.
- Hui et al. (2021). Inhibiting Monoacylglycerol Lipase Suppresses RANKL-Induced Osteoclastogenesis and Alleviates Ovariectomy-Induced Bone L…. Frontiers in Cell and Developmental Biology.
- Xu et al. (2020). Acanthopanax senticosus aqueous extract ameliorates ovariectomy-induced bone loss in middle-aged mice by inhibiting the …. Food & Function.
- Hui et al. (2020). NR1D1 modulates synovial inflammation and bone destruction in rheumatoid arthritis. Cell Death & Disease.
- Zhu et al. (2019). Vinpocetine inhibits RANKL-induced osteoclastogenesis and attenuates ovariectomy-induced bone loss. BIOMEDICINE & PHARMACOTHERAPY.
- Kazuaki et al. (2019). Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinson’s disease model mice. Scientific Reports.
- Liu et al. (2018). Hesperetin suppresses RANKL-induced osteoclastogenesis and ameliorates lipopolysaccharide-induced bone loss. JOURNAL OF CELLULAR PHYSIOLOGY.
- Cong et al. (2018). Effects of Taxifolin on Osteoclastogenesis in vitro and in vivo. Frontiers in Pharmacology.
- Zhang et al. (2018). (2R,3R)Dihydromyricetin inhibits osteoclastogenesis and bone loss through scavenging LPS-induced oxidative stress and NF…. JOURNAL OF CELLULAR BIOCHEMISTRY.
- Song et al. (2018). REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially viaFABP4 upregulation. FASEB JOURNAL.
- Libo et al. (2017). Dihydromyricetin Protects against Bone Loss in Ovariectomized Mice by Suppressing Osteoclast Activity. Frontiers in Pharmacology.
- Jiachao et al. (2017). Meclizine Prevents Ovariectomy-Induced Bone Loss and Inhibits Osteoclastogenesis Partially by Upregulating PXR. Frontiers in Pharmacology.
- Kong et al. (2017). Psoralidin suppresses osteoclastogenesis in BMMs and attenuates LPS-mediated osteolysis by inhibiting inflammatory cytok…. INTERNATIONAL IMMUNOPHARMACOLOGY.
- Dong et al. (2017). Inhibition of PRMT5 suppresses osteoclast differentiation and partially protects against ovariectomy-induced bone loss t…. CELLULAR SIGNALLING.
- Liu et al. (2017). Lipoxin A4 suppresses osteoclastogenesis in RAW264.7 cells and prevents ovariectomy-induced bone loss. EXPERIMENTAL CELL RESEARCH.
- Yong et al. (2015). Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss. Scientific Reports.
- Guan et al. (2014). Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss. FASEB JOURNAL.
- Mai et al. (2011). Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. JOURNAL OF CELLULAR BIOCHEMISTRY.
- (2025). Up-regulation of Ifi27l2a expression in bone marrow monocytes contributes to glucocorticoid-induced bone loss.